Bariatric surgery and cancer incidence
People with severe obesity who have weight-loss surgery develop about a third fewer cancers over the following decade, especially womb and other hormone-related cancers, than similar people who do not.
The Swedish Obese Subjects study (prospective, matched controls, more than 20 years' follow-up) and several large cohorts (SPLENDID, Cleveland Clinic, JAMA 2022, n=30,318) show that bariatric surgery is associated with a roughly 30-35% reduction in obesity-associated cancer incidence and lower cancer mortality, with the largest effects in endometrial cancer and in women. This is the strongest evidence that deliberately reversing obesity reduces cancer, though it remains non-randomised: no trial has randomised surgery with cancer as the outcome and the populations that undergo surgery differ from those that do not. A small increase in colorectal cancer risk after some procedures has been reported in Scandinavian registries and is unexplained. Whether GLP-1 receptor agonists reproduce the effect at scale is the live question.
How it works
Substantial, sustained weight loss lowers circulating insulin, oestrogens and inflammatory cytokines and reverses the metabolic and endometrial changes that drive obesity-related carcinogenesis.
- Large, long-term cohorts with matched controls
- Effect on endometrial cancer is large and biologically coherent
- Demonstrates reversibility of obesity-related cancer risk
- No randomised evidence
- Possible increased colorectal risk after some procedures
- Applies only to severe obesity
Latest papers
topQuery for this technology: (TITLE:"Bariatric surgery and cancer incidence" OR ABSTRACT:"Bariatric surgery and cancer incidence") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bariatric surgery and cancer incidence, not a curated reading list.
Pages like this
not linked directly; found by shared links- IdeaA trial of GLP-1 weight-loss drugs with cancer as the primary outcome
Shares Link bariatric and GLP-1 registries to cancer registries in every country that has both, GLP-1 receptor agonists and obesity-related cancer risk, Chemoprevention & risk-reducing surgery, Endometrial cancer.
- IdeaGLP-1 drugs to reverse endometrial precancer in women with obesity
Shares GLP-1 receptor agonists and obesity-related cancer risk, Chemoprevention & risk-reducing surgery, Endometrial cancer, Prevention we already have is not deployed.
- Key paperIARC verdict: excess body fat causes 13 cancers
Shares Endometrial cancer, Prevention we already have is not deployed, Renal cell carcinoma, Hepatocellular carcinoma.
- TechnologyUltra-processed food and sugar-sweetened drinks
Shares Obesity-related cancers (IARC list of 13), Prevention we already have is not deployed, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma.
- TechnologyAlcohol reduction, pricing and cancer warning labels
Shares Chemoprevention & risk-reducing surgery, Prevention we already have is not deployed, Hepatocellular carcinoma, HR-positive / HER2-negative breast cancer.
- IdeaEvaluate alcohol minimum unit pricing against cancer incidence
Shares Weak real-world evidence and registries, Prevention we already have is not deployed, Hepatocellular carcinoma, HR-positive / HER2-negative breast cancer.
- TermEnergy balance
Shares Metabolic syndrome and insulin resistance, GLP-1 receptor agonists and obesity-related cancer risk, Lipid synthesis, uptake & cholesterol, Obesity-related cancers (IARC list of 13).
- TechnologyStructured exercise programmes after curative treatment
Shares Metabolic syndrome and insulin resistance, Obesity-related cancers (IARC list of 13), Prevention we already have is not deployed, HR-positive / HER2-negative breast cancer.